LTR Pharma reports compelling clinical results for its nasal spray ED treatment SPONTAN®, demonstrating rapid absorption and strong safety, alongside strategic partnerships and a robust $34 million cash position.
Immuron Limited reports a striking 70% quarter-on-quarter increase in Travelan® sales, driven by expanded pharmacy distribution in Australia and North America.